by RNA Diagnostics | Sep 10, 2021 | Uncategorized
TORONTO, CANADA — (September 9, 2021) Rna Diagnostics Inc., a leading precision cancer diagnostics company, announced the closing of a CDN $8.0 M series A financing led by iGan Partners and BDC Capital, through its Bridge Financing Program. “The continued...
by RNA Diagnostics | Nov 8, 2018 | Uncategorized
Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced today the closing of a $5 million Series A financing. The funding was led by iGAN Partners and includes new and existing investors. Rna...
by RNA Diagnostics | May 24, 2018 | Uncategorized
NEW YORK (GenomeWeb) Rna Diagnostics, a Canadian molecular diagnostics company, recently commenced a clinical trial to validate an assay it plans to commercialize that can be used to guide breast cancer treatment. The trial, called Breast Cancer Response Evaluation...
by RNA Diagnostics | Apr 27, 2018 | Uncategorized
Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced enrollment of the first patient in the BREVITY trial at the Azienda Socio-Sanitaria Territoriale di Cremona in Cremona, Italy today....
by RNA Diagnostics | Jul 6, 2017 | Uncategorized
Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz, Consultant and Professor at Mayo Clinic, Rochester, MN has been appointed to the company’s Clinical Advisory Board (CAB). “Dr. Goetz brings a wealth of scientific knowledge and clinical trial experience...
by RNA Diagnostics | Jun 14, 2017 | Uncategorized
Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer. BREVITY (Breast Cancer Response EValuation for Individualized TherapY) will...
